We hypothesize lower socioeconomic status (SES) may lead to higher risk of mPCa regardless of race and insurance status and partly explain existing disparities in PCa outcomes. We therefore used a large national cancer registry to compare socioeconomic, demographic, and clinical characteristics of men presenting with and without mPCa.
INTRODUCTION AND OBJECTIVES:
We hypothesize lower socioeconomic status (SES) may lead to higher risk of mPCa regardless of race and insurance status and partly explain existing disparities in PCa outcomes. We therefore used a large national cancer registry to compare socioeconomic, demographic, and clinical characteristics of men presenting with and without mPCa.
METHODS: All men diagnosed with adenocarcinoma of the prostate in the National Cancer Data Base from 2004 to 2013 were identified. A four-level composite metric of SES was created using census-based income and education data. Multivariable logistic regression analysis was used to evaluate the association of various factors such as race/ethnicity and insurance status with the likelihood of presenting with mPCa while controlling for SES.
RESULTS: Of the 1,034,754 patients with PCa, 4% presented with mPCa. Metastatic PCa was diagnosed in 3% of patients in the highest SES group and 5% in the lowest SES group (lowest vs highest SES: adjusted OR 1.39, 95% CI 1.35-1.44, p<0.001). Likewise, having Medicaid or no insurance (12.5%; OR 3.91, 95% CI 3.78-4.05, p<0.001) was associated with greater odds of mPCa compared to having private insurance or Medicare (3.6%). Compared to White men (3.6%), Black (5.9%; adjusted OR 1.47, 95% CI 1.43-1.51, p<0.001) and Hispanic men (6.2%; OR 1.22, 95% CI 1.17-1.28; p<0.001) had higher odd of metastatic diagnoses. SES disparities in the diagnosis of mPCa were seen within race/ethnicity and insurance groups (Figure) . Decreasing SES lead to larger increases in the absolute risk of mPCa among Black and Hispanic men and men with Medicaid or no insurance compared to White men and men with private insurance or Medicare, respectively.
CONCLUSIONS: There is an inverse relationship between SES and odds of presenting with mPCa. Having no insurance or Medicaid and being of Black or Hispanic race/ethnicity increased odd of mPCa even when controlling for SES. Decreasing SES lead to increased risk of mPCa even within each race/ethnicity and insurance groups, especially for non-White men and men with Medicaid or no insurance. The effect of SES on mPCa presentation may partly explain existing disparities in PCa outcomes.
Source of Funding: NIH 5U01CA196390 and the Prostate
Cancer Foundation e Hagen Special Challenge.
PD03-08 IMPACT OF AGE, COMORBIDITY, AND PSA DOUBLING TIME ON LONG-TERM COMPETING RISKS FOR MORTALITY AMONG MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Colette Whitney, Lauren Howard, Durham, NC; Stephen Freedland, Los Angeles, CA; Christopher Amling, Portland, OR; William Aronson, Los Angeles, CA; Matthew Cooperberg, San Francisco, CA; Christopher Kane, San Diego, CA; Martha Terris, Augusta, GA; Timothy Daskivich*, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Given the protracted course of prostate cancer (PC) progression, competing risks of mortality is a key consideration in determining prognosis and treatment in all stages of the disease. We sought to examine the impact of age, Charlson Comorbidity Index (CCI), and PSA doubling time (PSADT) on all-cause mortality (ACM), prostate cancer-specific mortality (PCSM), and other-cause mortality (OCM) in a nationally representative sample of men with non-metastatic castration-resistant PC (M0/Mx CRPC).
METHODS: We analyzed 1,238 men diagnosed with M0/Mx CRPC in 2000 or later from 8 Veterans Affairs hospitals in the SEARCH database. CCI and PSADT were calculated at the time of M0/MX CRPC diagnosis, and cause of death was defined as PCSM or OCM. Men were divided into subgroups based on age (<70, 70-79, and 80), CCI (0, 1, 2, and 3þ), and PSADT (<9 months, 9 months). Multivariable Cox proportional hazards analysis and competing risks regression analysis were used to determine the relative impact of age, CCI, and PSADT on ACM, PCSM, and OCM. Models were adjusted for race, year of diagnosis, site, biopsy Gleason score, PSA at CRPC, primary Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e59 treatment, months from androgen deprivation to CRPC, and PSA velocity. RESULTS: Men in our sample were generally older (<70, n¼344; 70-79, n¼418; 80, n¼476), and the majority had CCI 2 (n¼701). Competing risk regression analysis revealed that the risk of PCSM was appreciable for all subgroups, particularly among those with PSADT<9mos. However, the hazard of OCM was substantially higher for older, sicker men with high PSADT (Figure 1 ). For example, among men aged 80, those with CCI 3 and PSADT9 mos, cumulative incidence of PCSM/OCM at 5 years was 20%/50% compared with 30%/ 19% for CCI 0 and PSADT<9mos. Multivariable analysis showed that higher comorbidity burden predicted higher hazard of OCM across all ages; among those with CCI 3 (vs. 0), hazard ratios for OCM were 2.7 (95%CI 1.1-6.3), 2.0 (95%CI 1.1-3.6), and 2.5 (95%CI 1.5-4.0) for those aged <70, 70-79, and 80, respectively.
CONCLUSIONS: Among men with M0/Mx CRPC, age, comorbidity, and PSADT are predictive of cause of death. Understanding the competing risks of PCSM and OCM is a critical consideration when counseling patients regarding prognosis and treatment of advanced PC. IN CALIFORNIA, 1988 -2014 Marc Dall'Era*, Ralph Devere White, Danielle Rodriguez, Rosemary Cress, Sacramento, CA INTRODUCTION AND OBJECTIVES: Early detection of prostate cancer with PSA based screening can reduce the risk of prostate cancer mortality by 21%. Screening for prostate cancer has dramatically declined in the United States since the United States Preventive Services Task Force (USPSTF) recommended against routine PSA based prostate cancer screening for all men in 2012. This led to dramatic reductions in the diagnosis of localized disease across all clinical risk groups. We sought to study trends in newly diagnosed metastatic prostate cancer incidence, specifically the impact of patient age and race.
Source of Funding: None

PD03-09 RISING INCIDENCE OF METASTATIC PROSTATE CANCER
METHODS: We analyzed new prostate cancer incidence by stage at diagnosis between 1988-2014 using data from the California Cancer Registry. We further stratified cases by age and four major race/ethnicity groups (non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic and non-Hispanic Asian/PI (API)). Incidence rates per 100,000 were age-adjusted to the 2000 US Standard Population. Joinpoint regression was used to detect changes in incidence and to calculate the average percent change (APC) over time. Joinpoint finds the best fit model with the smallest number of joinpoints and will not add an additional joinpoint if it does not make significant improvement on the model. RESULTS: Adjusted rates of remote prostate cancer incidence for men of all races aged 65-74 and NHW men of all ages significantly increased over the most recent time period by 2.4% and 1%, respectively, p<0.05 (Figure 1 and 2) . In contrast, incidence of remote prostate cancer continued to decline for NHB (-2.42%), Hispanic (-1.94%), and API (-1.66%) men. Localized disease incidence continues to decline significantly for all age and racial groups.
CONCLUSIONS: Incidence rates of newly metastatic prostate cancer have significantly increased for the first time in California for men aged 65-74 and white men. Although not possible to determine the etiology of these findings, decreased PSA screening and early detection of aggressive as well as indolent tumors is likely to contribute. The 2015 prostate cancer grading system was introduced to simplify pathologic stratification. We examine the performance of the Prognostic Grade Groups (PGG) in the Shared Equal Access Regional Cancer Hospital (SEARCH) database with respect to long term prostate cancer outcomes and whether associations vary by race within an equal access healthcare system. METHODS: We performed a retrospective review of men undergoing radical prostatectomy at one of six Veterans Affairs hospitals between 1988 and 2015. We identified 4,325 men with available data.
